4.7 Article

Carvacrol alleviates liver fibrosis by inhibiting TRPM7 and modulating the MAPK signaling pathway

Journal

EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 898, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.ejphar.2021.173982

Keywords

Carvacrol; CCl4-induced liver fibrosis; Transient receptor potential melastatin 7 (TRPM7); Hepatic stellate cells (HSCs); Mitogen-activated protein kinases (MAPK)

Funding

  1. National Natural Science Foundation of China [81600498]
  2. Foundation of Chinese Medical Association [320. 6750. 19090-17]
  3. Province Natural Science Foundation of Universities of Anhui Province [2020XKJ187]

Ask authors/readers for more resources

The study demonstrated that carvacrol could effectively reduce liver damage and the progression of liver fibrosis in mice by inhibiting the activation and proliferation of hepatic stellate cells. Additionally, it was found that carvacrol inhibits the expression of TRPM7 and mediates through the mitogen-activated protein kinases (MAPK) signaling pathway to inhibit the proliferation and activation of HSC-T6 cells.
Liver fibrosis is a compensatory response to the tissue repair process. The activation and proliferation of hepatic stellate cells (HSCs) are thought to be related to the occurrence of hepatic fibrosis. Therefore, inhibiting the activation and proliferation of HSCs is a key step in alleviating liver fibrosis. As a non-specific inhibitor of transient receptor potential melastatin 7 (TRPM7), carvacrol has anti-tumor, anti-inflammatory and anti-hepatic fibrosis activities. This study aimed to explore the protective effect of carvacrol on liver fibrosis and related molecular mechanisms. A CCl4-induced liver fibrosis mouse model and platelet-derived growth factor (PDGFBB)-activated HSC-T6 cells (a rat hepatic stellate cell line) were employed for in vivo and in vitro experiments. C57BL/6J mice were orally administered different concentrations of carvacrol every day for 6 weeks during the development of CCl4-induced liver fibrosis. The results show that carvacrol could effectively reduce liver damage and the progression of liver fibrosis in mice, which are expressed as fibrotic markers levels were reduced and histopathological characteristics were improved. Moreover, carvacrol inhibited the proliferation and activation of HSC-T6 cells induced by PDGF-BB. In addition, it was found that carvacrol inhibits the expression of TRPM7 and mediated through mitogen-activated protein kinases (MAPK). Collectively, our study shows that carvacrol can reduce liver fibrosis by inhibiting the activation and proliferation of hepatic stellate cells, and the MAPK signaling pathway might be involved in this process.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available